SCM Jeans/iStock Editorial via Getty Images Hexcel Corporation ( HXL ), the provider of composite materials for the aerospace and defense industry, reported Q1 2026 financial results that surpassed the estimates of analysts on the top and bottom line. The stock price has increased nearly 12% since my last report , sharply outperforming the S&P 500’s 3.5% return. While we see end market growth, the...
SCM Jeans/iStock Editorial via Getty Images Hexcel Corporation ( HXL ), the provider of composite materials for the aerospace and defense industry, reported Q1 2026 financial results that surpassed the estimates of analysts on the top and bottom line. The stock price has increased nearly 12% since my last report , sharply outperforming the S&P 500’s 3.5% return. While we see end market growth, there is also cost inflation risk, as I discuss in this report in support of my continued buy rating. Hexcel Operating Leverage Kicks In In the fourth quarter, Hexcel sales rose 9.9% and 8.8% on constant currency to $501.5 million. Operating income grew 30.3% to $57.6 million, with margins improving from 9.9% to 13.5%. This clearly signaled operating leverage, but we note that operating expenses as a share of revenue were higher year-on-year, with SG&A accounting for 9.9% of revenues compared to 9.5% a year ago and R&D accounting for 3.5% of revenues compared to 3% a year ago. In other words, we are seeing improving sales leverage on the gross margin level, but operating cost absorption is not yet happening in a favorable way. Commercial aerospace revenues for Hexcel (Hexcel (Earnings Presentation)) Commercial aerospace sales during the quarter grew 18.8% to $332.7 million, driven by the two wide body programs, namely the Airbus A350 and Boeing 787, and two single aisle programs, which are the Boeing 737 MAX and Airbus A320neo. The Airbus A350 and Boeing 787 programs have high-value composite shipset values, while the Boeing 737 MAX and Airbus A320neo are value drivers through volume. For the twelve-month trailing period, we see that sales rose 4.5% and are at a multi-year high. Having the big picture in mind is good, but we also note that by presenting twelve-month trailing figures, the company may at times not highlight quarterly sales improvements enough. This was such a quarter, as LTM figures show 4.5% growth while quarterly figures show nearly 19% growth. Hexcel defense ...
Shares in Agios Pharmaceuticals (NASDAQ: AGIO) crashed by 26.8% in the week as of the time of writing. The move comes after a much larger pharmaceutical company, Novo Nordisk (NYSE: NVO) , announced top-line results from a class of drug to treat sickle cell disease (SCD) that implied superiority over Agios' rival drug mitapavit. Both drugs, Novo's etavopivat and Agios' mitapivat, are in the same c...
Shares in Agios Pharmaceuticals (NASDAQ: AGIO) crashed by 26.8% in the week as of the time of writing. The move comes after a much larger pharmaceutical company, Novo Nordisk (NYSE: NVO) , announced top-line results from a class of drug to treat sickle cell disease (SCD) that implied superiority over Agios' rival drug mitapavit. Both drugs, Novo's etavopivat and Agios' mitapivat, are in the same class of oral pyruvate kinase (PK) activators that affect red blood cell metabolism in patients with sickle cell disease. However, Novo describes etavopivat as a pyruvate kinase-R (PKR) activator, reflecting that it specifically targets PKR (Protein Kinase R). Novo's top-line results from its Phase 3 trial demonstrated that etavopivat met both its primary endpoints of improving hemoglobin response and reducing vaso-occlusive crises (VOCs). Continue reading
A sudden downgrade of a state-backed financing vehicle in eastern China is exposing weaknesses in the country’s credit rating industry, raising concerns over hidden risks in the local government debt market. Qingdao Shanghe Holding Development Group Co. Ltd., a local government financing vehicle (LGFV), was cut from AAA to AA+ by major domestic rating agencies in early April after a 100 million yu...
A sudden downgrade of a state-backed financing vehicle in eastern China is exposing weaknesses in the country’s credit rating industry, raising concerns over hidden risks in the local government debt market. Qingdao Shanghe Holding Development Group Co. Ltd., a local government financing vehicle (LGFV), was cut from AAA to AA+ by major domestic rating agencies in early April after a 100 million yuan ($14.6 million) trust financing default drew regulatory scrutiny. The move followed months of overdue commercial paper.